Clinical Trials Logo

Acute Cough clinical trials

View clinical trials related to Acute Cough.

Filter by:
  • None
  • Page 1

NCT ID: NCT03569033 Terminated - Acute Cough Clinical Trials

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Start date: July 4, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in adult participants with induced viral upper respiratory tract infections (URTI).

NCT ID: NCT02396706 Completed - Acute Cough Clinical Trials

RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough

Start date: January 2015
Phase: Phase 2
Study type: Interventional

Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough

NCT ID: NCT01597349 Completed - Acute Cough Clinical Trials

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

Start date: May 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to learn how effective and safe FP01 lozenges are when given to subjects with a cough due to an upper respiratory tract infection. The study will include subjects who have an upper respiratory tract infection, with a cough of less than six weeks duration.

NCT ID: NCT00547846 Completed - Acute Cough Clinical Trials

A Phase II Clinical Study of PDC-748 in Patients With Acute Cough

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The pharmacological effects of PDC-748 were tested in numerous in vitro and in vivo studies. The existing pharmacologic findings suggest that PDC-748 possesses certain inhibitory activity to the citric acid- and capsaicin-induced cough reflex in guinea pigs with a dose-dependent manner. Furthermore, a previous Phase I/II uncontrolled, dose-escalating study has shown PDC-748 to be well tolerated and may help to alleviate daytime cough with a dose-responding manner.Hence, PhytoHealth Corporation intends to carry out a Phase II investigation to confirm the preliminary findings using placebo in the comparator group, and to further investigate PDC-748 with a dose escalating manner to establish the dose-response range for its antitussive effect, and if possible, to determine the maximal tolerable dose of PDC-748. This is a randomized, double-blind, placebo-controlled, dose escalating study to evaluate the safety and efficacy of the escalating dose levels of PDC-748 in patients with acute cough.